Evaluation of megakaryocyte morphology is difficult but can be essential for the diagnosis of myelodysplastic syndromes (MDS) and other myeloid neoplasms. We agreed upon descriptions and provided images of megakaryoblasts and of normal and dysplastic megakaryocytes, which were used as a basis for assessing the concordance of expert morphologists in their recognition. We showed a high rate of concordance for the recognition of micromegakaryocytes and confirmed their strong association with hematologic neoplasia, including MDS. Concordance was also found to be good for the recognition of multinucleated megakaryocytes, which showed a significant association with MDS. However cytoplasmic abnormalities were found not to be useful in MDS recognit...
Myelodysplastic syndromes (MDS) are hematopoietic stem cell disorders characterized by dysplastic, i...
Myelodysplastic syndromes (MDS) are hematopoietic stem cell disorders characterized by dysplastic, i...
On behalf of the PETHEMA/GEM Cooperative Group.Risk of developing myelodysplastic syndrome (MDS) is ...
Evaluation of megakaryocyte morphology is difficult but can be essential for the diagnosis of myelod...
Evaluation of megakaryocyte morphology is difficult but can be essential for the diagnosis of myelod...
International audienceEvaluation of megakaryocyte morphology is difficult but can be essential for t...
The diagnosis of myelodysplastic syndromes is based on the presence of cytopenias, dysplastic morpho...
The World Health Organization classification of myelodysplastic syndromes (MDS) is based on morpholo...
Background: Thrombocytopenia may be encountered in various hematological and nonhematological condit...
The World Health Organization classification of myelodysplastic syndromes (MDS) is based on morpholo...
Additional file 1. Distribution of dysplastic megakaryocytes in subjects and variables of subjects w...
International audienceStudies of morphology of myelodysplastic syndromes (MDS) or acute myeloid leuk...
International audienceAn evaluation of the significance of specified dyserythropoietic features in s...
Summary: Morphogenesis of micromegakaryocytes in MDS was investigated in a case of refractory anemia...
Background: Thrombocytopenia is defined as platelet count less than 150,000 /mm3 (150x109 /litre) an...
Myelodysplastic syndromes (MDS) are hematopoietic stem cell disorders characterized by dysplastic, i...
Myelodysplastic syndromes (MDS) are hematopoietic stem cell disorders characterized by dysplastic, i...
On behalf of the PETHEMA/GEM Cooperative Group.Risk of developing myelodysplastic syndrome (MDS) is ...
Evaluation of megakaryocyte morphology is difficult but can be essential for the diagnosis of myelod...
Evaluation of megakaryocyte morphology is difficult but can be essential for the diagnosis of myelod...
International audienceEvaluation of megakaryocyte morphology is difficult but can be essential for t...
The diagnosis of myelodysplastic syndromes is based on the presence of cytopenias, dysplastic morpho...
The World Health Organization classification of myelodysplastic syndromes (MDS) is based on morpholo...
Background: Thrombocytopenia may be encountered in various hematological and nonhematological condit...
The World Health Organization classification of myelodysplastic syndromes (MDS) is based on morpholo...
Additional file 1. Distribution of dysplastic megakaryocytes in subjects and variables of subjects w...
International audienceStudies of morphology of myelodysplastic syndromes (MDS) or acute myeloid leuk...
International audienceAn evaluation of the significance of specified dyserythropoietic features in s...
Summary: Morphogenesis of micromegakaryocytes in MDS was investigated in a case of refractory anemia...
Background: Thrombocytopenia is defined as platelet count less than 150,000 /mm3 (150x109 /litre) an...
Myelodysplastic syndromes (MDS) are hematopoietic stem cell disorders characterized by dysplastic, i...
Myelodysplastic syndromes (MDS) are hematopoietic stem cell disorders characterized by dysplastic, i...
On behalf of the PETHEMA/GEM Cooperative Group.Risk of developing myelodysplastic syndrome (MDS) is ...